Mylonakis E, Ausubel FM, Perfect JR, Heitman J, Calderwood SB. Killing of Caenorhabditis elegans by Cryptococcus neoformans as a model of yeast pathogenesis. Proc Natl Acad Sci USA 2002; 99:15675-80.

Mylonakis E, Idnurm A, Moreno R, El Khoury J, Rottman JB, Ausubel FM, Heitman J, Calderwood SB. Cryptococcus neoformans Kin1 protein kinase homolog, identified through a C. elegans screen, promotes virulence in mammals. Mol Microbiol 2004; 54:407-19.

Apidianakis Y, Rahme LG,  Heitman J, Ausubel FM, Calderwood SB, Mylonakis E. Challenge of Drosophila melanogaster with Cryptococcus neoformans and the role of the fly Innate immune response. Eukaryot Cell 2004; 3:413-9.

Mylonakis E, Moreno R, El Khoury J, Idnurm A, Heitman J, Calderwood SB, Ausubel FM, Diener A. Galleria mellonella as a model system to study Cryptococcus neoformans pathogenesis. Infect Immun 2005; 73: 3842-50.

Mylonakis E, Aballay A. Worms and flies as genetically tractable animal models to study host-pathogen interactions. Infect Immun 2005;73:3833-41.

Tang RJ, Breger J, Idnurm A, Gerik K, Lodge JK, Heitman J, Calderwood SB, Mylonakis E. Cryptococcus neoformans gene involved in mammalian pathogenesis identified by a C. elegans progeny-based approach. Infect Immun 2005; 73: 8219-25. http://iai.asm.org/cgi/reprint/73/12/8219

Aperis G, Mylonakis E. New triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations. Expert Opin Investig Drugs. 2006;15:579-602.

Kwon DS, Mylonakis E. Posaconazole: A new broad-spectrum antifungal agent. Expert Opin Pharmacother. 2007;8:1167-78.

Mylonakis E, Casadevall A, Ausubel FM. Exploiting amoeboid and non-vertebrate animal model systems to study the virulence of human pathogenic fungi. PLoS Pathog. 2007;3:e101. http://www.plospathogens.org/article/info:doi/10.1371/journal.ppat.0030101

Mylonakis E, Pukkila-Worley R. Epidemiology and management of cryptococcal meningitis: developments and challenges. Expert Opin Pharmacother. 2008;9:551-60.

Maadani A., Fox KA, Mylonakis E, Garsin DA. Enterococcus faecalis mutations affecting virulence in the C. elegans model host. Infect Immun. 2007;75:2634-7.

Aperis G, Fuchs BB, Anderson CA, Warner JE, Calderwood SB, Mylonakis E. Galleria mellonella as a model host to study infection by the Francisella tularensis live vaccine strain. Microbes Infect. 2007; 9:729-34.

Fuchs BB, Tang RJ, Mylonakis E. The temperature-sensitive role of Cryptococcus neoformans ROM2 in cell morphogenesis. PLoS ONE. 2007;2:e368.

http://www.plosone.org/article/info:doi/10.1371/journal.pone.0000368

Breger J, Fuchs BB, Aperis G, Moy T, Ausubel FM, Mylonakis E. Antifungal chemical compounds identified using a C. elegans pathogenicity assay. PLoS Pathog. 2007;3:e18.

Fuchs BB, Tegos GP, Hamblin MR, Mylonakis E. Susceptibility of Cryptococcus neoformans to photodynamic inactivation is associated with cell wall integrity. Antimicrob Agents Chemother. 2007;51:2929-36. http://aac.asm.org/cgi/reprint/51/8/2929

Thakur JK, Arthanari H, Yang F, Pan S-J, Fan X, Breger J, Frueh DP, Gulshan K, Li D, Mylonakis E, Struhl K, Moye-Rowley WS, Cormack BP, Wagner G, Näär AM. A nuclear receptor-like pathway regulating multidrug resistance in fungi. Nature 2008; 452:604-9.

Mylonakis E. Who killed the worm and other fungal pathogenesis insights. Microbe 2007;2:600-6.http://www.asm.org/microbe/index.asp?bid=55040

Peleg AY, Monga D, Pillai S, Mylonakis E, Moellering RC Jr., Eliopoulos GM. Reduced susceptibility to vancomycin influences pathogenicity in Staphylococcus aureus. J Infect Dis (in press).

Tampakakis E, Okoli I, Mylonakis E. A C. elegans-based, whole animal, in vivo screen for the identification of antifungal compounds. Nature Protocols. (in press).

Peleg A, Tampakakis E, Fuchs BB, Eliopoulos G, Moellering RC Jr, Mylonakis E Prokaryote-eukaryote interactions identified using Caenorhabditis elegans. Proc Natl Acad Sci USA. 2008;105:14585-90. http://www.pnas.org/content/105/38/14585